Saturday 17 October 2026
Export MIRM’s income statement to Excel — free account
Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024. In the quarter to June 2026, revenue grew 37.9%, EPS fell 783.3%, free cash flow fell 681.5% and total debt rose 142.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
80.14
2.25
−2.73%
Follow MIRM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 6 | 4 | 3 |
| (15.81%) | (8.65%) | (335.82%) | (702.97%) | ||
| (5.70%) | (3.09%) | (101.04%) | (97.15%) | ||
ROIC |
(11.56%) | (5.74%) | (298.98%) | (172.96%) | |
Return on Tangible Assets |
(11.15%) | (6.76%) | (267.15%) | (206.89%) | |
Average Days of Receivables |
82.88 | 86.35 | 85.30 | 85.84 | |
Free Cash Flow per Share |
0.88 | 1.09 | (3.44) | (4.32) | |
Free Cash Flow |
44.32 | 54.87 | (202.55) | (273.74) | |
Capital Expenditures |
(0.37) | (0.95) | (31.58) | (46.47) | |
| Other line items | |||||
Cash ROIC |
4.54% | 5.44% | (21.57%) | (23.24%) | |
Accounts Receivable Turnover |
5.37 | 5.17 | 4.98 | 4.90 | |
Accounts Payable Turnover |
8.73 | 8.27 | 2.99 | 5.50 | |
Inventory Turnover |
4.15 | 4.24 | 4.42 | 4.64 | |
Average Days of Payables |
46.87 | 35.01 | 204.48 | 75.70 | |
Days of Inventory on Hand |
92.53 | 90.62 | 87.85 | 83.27 | |
Tax Rate |
0.01 | 0.09 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
37.96% | 35.71% | 169.30% | 165.88% | |
Selling, General and Administrative Expense of Revenue |
50.81% | 49.30% | 51.90% | 50.78% | |
Share Based Compensation of Revenue |
13.91% | 13.70% | 16.12% | 16.82% | |
Interest Coverage |
(2.91) | (1.54) | (55.27) | (62.06) | |
Operating CF/Net income |
(1.08) | (2.39) | 0.21 | 0.26 | |
Depreciation/Fixed assets |
20.32 | 13.95 | 11.12 | 12.41 | |
Capex/Depreciation |
(0.01) | (0.04) | (1.18) | (1.66) | |
Revenue per Share |
9.32 | 10.39 | 9.68 | 9.75 | |
Operating CF per Share |
0.88 | 1.11 | (2.91) | (3.59) | |
Capex per Share |
(0.01) | (0.02) | (0.54) | (0.73) | |
Capex to Sales |
0.00 | 0.00 | 0.06 | 0.08 |
Columns are period end dates